These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33041181)

  • 1. Azithromycin prophylaxis after lung transplantation is associated with improved overall survival.
    Li D; Duan Q; Weinkauf J; Kapasi A; Varughese R; Hirji A; Lien D; Meyer S; Laing B; Nagendran J; Halloran K
    J Heart Lung Transplant; 2020 Dec; 39(12):1426-1434. PubMed ID: 33041181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.
    Todd JL; Neely ML; Finlen Copeland CA; Frankel CW; Reynolds JM; Palmer SM
    J Heart Lung Transplant; 2019 Feb; 38(2):184-193. PubMed ID: 30466803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Montelukast in chronic lung allograft dysfunction after lung transplantation.
    Vos R; Eynde RV; Ruttens D; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck DE; Verleden GM;
    J Heart Lung Transplant; 2019 May; 38(5):516-527. PubMed ID: 30638839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
    Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
    J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung volumes predict survival in patients with chronic lung allograft dysfunction.
    Kneidinger N; Milger K; Janitza S; Ceelen F; Leuschner G; Dinkel J; Königshoff M; Weig T; Schramm R; Winter H; Behr J; Neurohr C
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28404648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of CT-SCAN score and volume measures to early identify restrictive allograft syndrome in single lung transplant recipients.
    Philippot Q; Debray MP; Bun R; Frija-Masson J; Bunel V; Morer L; Roux A; Picard C; Jebrak G; Dauriat G; Castier Y; Cazes A; Mal H; Taupin JL; Couffignal C; Brugière O
    J Heart Lung Transplant; 2020 Feb; 39(2):125-133. PubMed ID: 31836403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.
    DerHovanessian A; Todd JL; Zhang A; Li N; Mayalall A; Finlen Copeland CA; Shino M; Pavlisko EN; Wallace WD; Gregson A; Ross DJ; Saggar R; Lynch JP; Belperio J; Snyder LD; Palmer SM; Weigt SS
    Ann Am Thorac Soc; 2016 May; 13(5):627-35. PubMed ID: 27144793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
    Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
    J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
    Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Vanaudenaerde BM; Somers J; Schoonis A; Schaevers V; Van Raemdonck DE; Neyrinck A; Dupont LJ; Yserbyt J; Verleden GM; Vos R
    Am J Transplant; 2016 Jan; 16(1):254-61. PubMed ID: 26372728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline lung allograft dysfunction is associated with impaired survival after double-lung transplantation.
    Liu J; Jackson K; Weinkauf J; Kapasi A; Hirji A; Meyer S; Mullen J; Nagendran J; Lien D; Halloran K
    J Heart Lung Transplant; 2018 Jul; 37(7):895-902. PubMed ID: 29602706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial.
    Van Herck A; Frick AE; Schaevers V; Vranckx A; Verbeken EK; Vanaudenaerde BM; Sacreas A; Heigl T; Neyrinck AP; Van Raemdonck D; Dupont LJ; Yserbyt J; Verleden SE; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Mar; 38(3):252-259. PubMed ID: 30686699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study.
    Testaert H; Bouet M; Valour F; Gigandon A; Lafon ME; Philit F; Sénéchal A; Casalegno JS; Blanchard E; Le Pavec J; Ader F
    Clin Microbiol Infect; 2021 Jun; 27(6):897-903. PubMed ID: 32827713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.
    Greer M; Dierich M; De Wall C; Suhling H; Rademacher J; Welte T; Haverich A; Warnecke G; Ivanyi P; Buchholz S; Gottlieb J; Fuehner T
    Am J Transplant; 2013 Apr; 13(4):911-918. PubMed ID: 23406373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a post-transplant chronic lung allograft dysfunction classification system.
    Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome.
    Jain R; Hachem RR; Morrell MR; Trulock EP; Chakinala MM; Yusen RD; Huang HJ; Mohanakumar T; Patterson GA; Walter MJ
    J Heart Lung Transplant; 2010 May; 29(5):531-7. PubMed ID: 20133163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Recipients with Chronic Rejection.
    Combs MP; Luth JE; Falkowski NR; Wheeler DS; Walker NM; Erb-Downward JR; Wakeam E; Sjoding MW; Dunlap DG; Admon AJ; Dickson RP; Lama VN
    Am J Respir Crit Care Med; 2024 Jun; 209(11):1360-1375. PubMed ID: 38271553
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose computed tomography volumetry for subtyping chronic lung allograft dysfunction.
    Saito T; Horie M; Sato M; Nakajima D; Shoushtarizadeh H; Binnie M; Azad S; Hwang DM; Machuca TN; Waddell TK; Singer LG; Cypel M; Liu M; Paul NS; Keshavjee S
    J Heart Lung Transplant; 2016 Jan; 35(1):59-66. PubMed ID: 26342441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.
    Combs MP; Xia M; Wheeler DS; Belloli EA; Walker NM; Braeuer RR; Lyu DM; Murray S; Lama VN
    J Heart Lung Transplant; 2020 Aug; 39(8):815-823. PubMed ID: 32360292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline lung allograft dysfunction in primary graft dysfunction survivors after lung transplantation.
    Li D; Weinkauf J; Kapasi A; Hirji A; Varughese R; Lien D; Nagendran J; Halloran K
    Respir Med; 2021 Nov; 188():106617. PubMed ID: 34571454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.